Lonza Group

Virtual Booth Global Pharmaceutical Dosage Solutions Company

Switzerland

Contact Supplier

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810

Lead Product(s): ATYR2810

Therapeutic Area: Oncology Product Name: ATYR2810

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: aTyr Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership April 14, 2021

Details:

Under the terms of the agreement, Lonza will utilize its Ibex® Design, a fully integrated end-to-end program, to manufacture cGMP material for ATYR2810.

Lonza Group

Virtual Booth Global Pharmaceutical Dosage Solutions Company

Switzerland

Contact Supplier

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

PsiVac and Lonza Enter a Strategic Agreement for the Process Development and cGMP Manufacturing of Ixovex-1

Lead Product(s): Ixovex-1

Therapeutic Area: Oncology Product Name: Ixovex-1

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: PsiVac

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 08, 2021

Details:

Under the terms of the parties’ strategic agreement, PsiVac will grant Lonza the exclusive right to cGMP manufacture the Ixovex-1 product.

Lonza Group

Virtual Booth Global Pharmaceutical Dosage Solutions Company

Switzerland

Contact Supplier

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Aruvant Chooses Lonza to Manufacture ARU-1801

Lead Product(s): ARU-1801

Therapeutic Area: Genetic Disease Product Name: ARU-1801

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Aruvant Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 18, 2021

Details:

The agreement aims to support ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). Aruvant has chosen Lonza to help develop and manufacture ARU-1801 for its upcoming pivotal trial.

Lonza Group

Virtual Booth Global Pharmaceutical Dosage Solutions Company

Switzerland

Contact Supplier

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Capricor Collaborates with Lonza for the Development of CAP-1002

Lead Product(s): Allogeneic cardiosphere-derived cells

Therapeutic Area: Genetic Disease Product Name: CAP-1002

Highest Development Status: Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Capricor Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 12, 2021

Details:

Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply.